ZORYVE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZORYVE (ZORYVE).
ZORYVE (roflumilast) is a selective phosphodiesterase-4 (PDE4) inhibitor. It inhibits the degradation of cyclic AMP (cAMP), leading to increased intracellular cAMP levels, which reduces the release of pro-inflammatory cytokines and mediators from various immune cells (e.g., neutrophils, eosinophils, macrophages).
| Metabolism | Primarily metabolized by CYP3A4 and CYP1A2 to its active N-oxide metabolite (roflumilast N-oxide). |
| Excretion | Fecal (approximately 90% of absorbed dose as unchanged drug and metabolites), renal (approximately 10% as metabolites). |
| Half-life | Terminal elimination half-life is approximately 28 hours; steady-state achieved within 2 weeks with once-daily dosing. |
| Protein binding | Approximately 99% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Approximately 0.7 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Topical: Approximately 5% systemic absorption; oral: not applicable (not available orally). |
| Onset of Action | Topical: Reduction in plaque elevation, erythema, and scaling observed within 2 weeks of twice-daily application. |
| Duration of Action | Sustained effect with once-daily dosing; clinical improvement maintained for up to 8 weeks of continuous use. |
Topical: Apply once daily to affected areas. For plaque psoriasis, use 0.3% cream; for seborrheic dermatitis, use 0.3% foam.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required based on GFR. |
| Liver impairment | No dose adjustment required for Child-Pugh A or B. For Child-Pugh C, use with caution; no specific dose recommendation. |
| Pediatric use | Safety and efficacy in pediatric patients below 12 years have not been established. |
| Geriatric use | No specific dose adjustment; elderly may have increased skin fragility, monitor for adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ZORYVE (ZORYVE).
| Breastfeeding | No data on presence in human milk, effects on breastfed infant, or milk production. In animal studies, roflumilast and its metabolites were present in rat milk at concentrations similar to maternal plasma. Based on topical administration, systemic exposure is minimal (<5% bioavailability); therefore, transfer to breast milk is expected to be negligible. M/P ratio not determined in humans. |
| Teratogenic Risk | No adequate and well-controlled studies in pregnant women. In animal studies, oral administration of roflumilast during organogenesis produced fetal developmental toxicity (including increased post-implantation loss, reduced fetal body weight, and delayed ossification) at exposures approximately 100 times the maximum recommended human dose (MRHD). However, with topical application, systemic exposure is minimal (<5% bioavailability), resulting in negligible fetal exposure. Therefore, based on topical route, risk is expected to be low. First trimester: insufficient data; second and third trimesters: same as first, but theoretical risk remains low due to minimal systemic absorption. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Moderate-to-severe liver impairment (Child-Pugh B or C)"]
| Precautions | ["Not for ophthalmic, oral, or intravaginal use","Patients with moderate-to-severe liver impairment: not recommended","May cause hypersensitivity reactions, including contact dermatitis","Use in pregnant women: limited data; consider risk vs benefit"] |
Loading safety data…
| Fetal Monitoring | No specific monitoring required beyond routine pregnancy care. However, if used during pregnancy, monitor for any signs of maternal systemic adverse effects (e.g., weight loss, gastrointestinal symptoms) due to extremely low systemic absorption with topical use. Fetal monitoring not indicated. |
| Fertility Effects | No human data. In animal studies, oral roflumilast had no adverse effects on male or female fertility at exposures up to approximately 100 times the MRHD. With topical use, systemic exposure is minimal; thus, no impact on fertility is expected. |